Co-founder
Biotech executive with operational experience across two PE-backed companies that achieved successful exits: SPT Labtech (acquired by EQT Ventures) and Velsera (Summa Equity portfolio). Led go-to-market strategy at Synthace, scaling revenue from startup to £12M+. Has facilitated over £10M in capital allocation across 100+ biotech ventures through the SynbiCITE accelerator programme. Currently advises clinical-stage biotechnology companies on Series A funding strategies, including A28 Therapeutics. Experience spans institutional partnership development, commercial operations, and capital structuring within the biotechnology sector. Law degree (BPP), mMBA and MRes Synthetic Biology (Imperial College London and University College London).